The danger of diazoxide in the neonatal intensive care unit.
Jay DesaiLogan KeyAlyson SwindallKan GastonAjay J TalatiPublished in: Therapeutic advances in drug safety (2021)
The dangers in diazoxide Newborns could experience a transient period of low blood glucose levels soon after birth. However, some may progress to persistent low blood glucose levels that cannot be controlled with adequate glucose infusion and may require other ways of treatment. Diazoxide is the first-line drug approved by the US Food and Drug Administration (FDA) for this condition. However, certain cases have reported the development of respiratory deterioration, including increased blood pressure in lung circulation after its use. This prompted a black box warning in 2015 by the FDA. The incidence of neonatal low blood glucose levels seems to have increased and so has the use of this drug. Our study identifies 15 newborns who received diazoxide at Regional One Health neonatal intensive care unit in the past 6 years and reports a significantly higher rate of adverse events in our population leading to drug discontinuation in almost 53% of our cases.
Keyphrases
- blood glucose
- blood pressure
- drug administration
- glycemic control
- preterm infants
- gestational age
- pregnant women
- adverse drug
- healthcare
- low birth weight
- public health
- mental health
- risk factors
- low dose
- type diabetes
- genome wide
- hypertensive patients
- drug induced
- health information
- gene expression
- skeletal muscle
- insulin resistance
- adipose tissue
- dna methylation
- health promotion
- combination therapy